MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Linsitinib

CAS No. : 867160-71-2

MCE 站：Linsitinib

产品活性：Linsitinib (OSI-906) 是一种有效选择性的，具有口服活性的 IGF-1 和胰岛素受体 (IR) 的双重抑制剂，IC₅₀ 分别为 35 和 75 nM。

研究领域：Protein Tyrosine Kinase/RTK

作用靶点：IGF-1R  |  Insulin Receptor

In Vitro: Linsitinib inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC₅₀ of 0.028 to 0.13 μM. Linsitinib enables an intermediate conformation of the target protein through interactions with the C-helix. Linsitinib displays favorable metabolic stability in liver microsomes. Linsitinib fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. Linsitinib inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC₅₀?of 0.021 to 0.810 μM.

In Vivo: Linsitinib inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg.?Linsitinib administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. Linsitinib administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax?is not dose-proportional to Linsitinib dose. Linsitinib elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. Linsitinib administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM.?Linsitinib administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. Linsitinib inhibits the growth of tumors in NCI-H292 xenograft mouse model.

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Kinase Inhibitor Library  |  Protein Tyrosine Kinase Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Differentiation Inducing Compound Library  |  Diabetes Related Compound Library  |  Endocrinology Compound Library  |  Anti-COVID-19 Compound Library  |  Orally Active Compound Library  |  Anti-Lung Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Insulin (human)  |  Insulin(cattle)  |  Picropodophyllin  |  BMS-536924  |  GSK1904529A  |  MSDC 0160  |  AZD-3463  |  NVP-TAE 226  |  AG1024  |  AGL-2263  |  S961 TFA  |  Ginsenoside Rg5  |  PQ401  |  GIP, human  |  Kaempferitrin  |  Rhoifolin  |  NBI-31772 hydrate  |  GIP (1-30) amide, porcine TFA  |  GIP (1-30) amide,human acetate  |  MID-1  |  GIP (3-42), human  |  I-OMe-Tyrphostin AG 538  |  KU14R  |  SU4984  |  Indirubin Derivative E804

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。